Conestoga Capital Advisors reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,000 ... Ticker Report, 9 hours ago
BLB&B Advisors Increases Stake in Merck & Co., Inc. (MRK) - Zolmax News, 9 hours ago
Cornerstone Advisors Inc. Has $270,000 Stake in Merck & Co., Inc. (MRK) - WKRB News, 12 hours ago
NEW DELHI: US drug maker Merck has introduced Zostavax, its vaccine brand that prevents a painful viral infection. The product that posted worldwide sales of over $750 million (Rs5,133 crore) in 2014 will now be available here at Rs7,500-8,000 ...Economic Times, 18 hours ago
Sun Pharmaceutical Industries and Merck Sharp & Dohme (MSD) have decided to terminate a joint venture to develop, manufacture and commercialise branded generics for emerging markets. Sun Pharma today said the partners had put in significant efforts to pursue ...The Telegraph, 1 day ago Sun Pharma to end venture with Merck & Co Business Line, 1 day ago Merck & Co., Sun Pharmaceutical terminate branded-generics joint venture FirstWord Pharma, 1 day ago Sun Pharma Shares Jump After Quarterly Earnings Beat Estimates Equilibrio Informativo, 1 day ago
A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014. Reuters/Danish Siddiqui/Files MUMBAI India's largest drugmaker, Sun Pharmaceutical Industries Ltd( ...Reuters India, 1 day ago Sun Pharma Q3 profit beats Street, to wind down JV with Merck Reuters, 1 day ago Sun Pharma's Q3 profit beats estimates Sify, 1 day ago Sun Pharma to seek FDA re-inspection of Halol plant by end-June Reuters UK, 1 day ago
Merck Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 26, 2016, to consider and approve the audited financial results for the year ended December 31, 2015 and to consider recommendation of dividend for the ...Money Control, 1 day ago
Filing Date 2016-02-10 Accepted 2016-02-10 16:28:20 Documents 1 Period of Report 2016-02-08 Filing Date Changed 2016-02-10 Document Format Files Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 ...SEC, 3 days ago 4 - Merck Sharp & Dohme Corp. (0000942443) (Reporting) SEC, 3 days ago Merck & Co., Inc. (0000310158) (Subject) SEC Filings, 3 days ago Merck & Co., Inc. (0000310158) (Filed by) SEC Filings, 1 day ago
Technology and pharma company Merck is open for applications to its second accelerator programme for digital health in Nairobi, Kenya this April. Startups will receive equity-free funding of $15,000 funding, three months coaching and mentoring as ...Biz Community, 3 days ago Merck launches Accelerator Program for Digital Healthcare in Nairobi Africa-On The Rise, 2 days ago Merck moves into Kenya with equity-free accelerator digital healthcare Tekedia, 4 days ago Merck's digital health accelerator expands into Africa PC Tech Magazine, 5 days ago
News Editor The FDA approves Lannett Company's (NYSE:LCI) temozolomide capsules, its generic equivalent to Merck's (NYSE:MRK) chemo drug Temodar Capsules. According to IMS, annual U.S. sales of the branded product areSeeking Alpha, 2 days ago Lannett passes US FDA approval for chemotherapy agent Temozolomide Bloomberg, 1 day ago Glenmark Pharma tanks 5% on patent infringement lawsuit; FDA nod goes in vain India Infoline, 2 months ago
T-Hub Health Tech Innovation Accelerator will be set up in partnership with pharmaceutical major Merck and Microsoft VenturesBusiness Standard, 2 days ago T-Hub to launch accelerator programme in April The Hindu, 2 days ago T-Hub to launch its first accelerator for health-tech startups Economic Times, 3 days ago
IMMUNOGEN : and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® pembrolizumab for the...
ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® pembrolizumab for the Treatment of Ovarian Cancer By a News Reporter-Staff News Editor at Clinical Trials Week -- ...4 Traders, 2 days ago ImmunoGen, Merck collaborate on clinical study of mirvetuximab soravtansine in combo with Keytruda to treat ovarian cancer PharmaBiz, 1 week ago ImmunoGen to evaluate combo of lead product candidate and Merck's Keytruda in ovarian cancer Seeking Alpha, 1 week ago ImmunoGen, Merck & Co. Launch Cancer ... Genetic Engineering News, 1 week ago
on your WebpageAdd Widget >Get your members hooked!